New anti-VEGF agents for wet age-related macular degeneration can extend injection intervals to 3-5 months but may increase ...

Patients with challenging diabetic macular edema may achieve anatomical gains and extended dosing intervals with bispecific faricimab.

EyePoint Pharmaceuticals completed enrollment in the LUCIA trial, its second phase 3 trial of Duravyu in patients with wet ...

June 30, 2025, expected to fund planned operations into 2028 EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage ...

D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedulePresented positive 60-week res ...

Second-Quarter 2025 and Recent Selected Highlights: <li /> Total revenues of $63.7 million, a 30% increase over $48.

AQUARIUS, the second Phase 3 study, is anticipated to initiate in the fourth quarter of 2025, pending funding availability. Long-term follow-up from the LUNA Phase 2 study continues, with two-year ...

Recently, VivaVision Biotech (Zhejiang) Co., Ltd. (VivaVision) announced the appointment of Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS to its Scientific Advisory Board.

Gain insights into EyePoint Pharmaceuticals' Q2 2025 performance, featuring DURAVYU's Phase III progress in wet-AMD, global expansion, and ...

A new study finds cuts in copay assistance for retina injections are harming lower-income communities and leading to poorer ...

Detailed price information for Eyepoint Pharmaceuticals Inc (EYPT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.